Stocks · News reference
This Intuitive Surgical Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Top analysts upgraded IDEX and Entegris, raised price targets. Intuitive Surgical upgraded with $500 target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NSF Welcomes Hanjun Kwon, Managing Director, APAC
NSF, a global human health organization, has appointed Hanjun Kwon as Managing Director for the Asia-Pacific region. Kwon brings two decades of international leadership experience from companies including Entegris, Honeywell, Henkel, and Dow Corning. He will lead efforts to drive sustainable growth and strengthen NSF's position in food, water, and wellness across APAC, including the upcoming launch of a new drinking water safety standard in Southeast Asia.
Shares of semiconductor and chip-related companies are trading lower after AI executives signaled that the industry's growth may need to be slowed. The industry is also facing pressure as oil prices spike in reaction to the escalating conflict in the Middle East which can lead to inflation, tighter lending and reduced demand.
Shares of semiconductor and chip companies are trading lower as energy prices, rate expectations and bond yields converge to weigh on the demand outlook for sectors that are exposed to highly leveraged capex cycles.
Oppenheimer Maintains Outperform on IDEX, Raises Price Target to $270
Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
Medtronic's stock is down 3% this year despite strong fundamentals, presenting a buying opportunity for growth-oriented investors. The company's Hugo robotic-assisted surgery system is gaining traction and eroding competitor Intuitive Surgical's market dominance. With Q1 FY2027 revenue up 13.7% YoY, raised full-year guidance, a near-Dividend King status (49 consecutive years of dividend increases), and attractive valuation metrics, analysts view the stock as undervalued compared to peers.